

Current Priority Management Issues and Business Strategy

November 30, 2016



Masakazu Tokura President

Contents

I . Overview of FY2016 Outlook P. 3-7

II. Corporate Business Plan P. 8-13

II. Challenges and Strategy for Our Major Businesses (Efforts to Create New Value)

P.14-47

IV. Sumitomo Chemical's Value Creation

P.48-55



Overview of FY2016 Outlook

FY2016 Forecast vs. FY2015

(Billions of yen)

FY2015
2,101.8
164.4
20.2
171.2
81.5

FY2016 Forecast
1,960.0
120.0
30.0
130.0
60.0

Naphtha Price
Exchange Rate

¥42,800/kl	
¥120.15/\$	

¥32,700/kl
¥105.10/\$


FY2016 Operating Income Forecast By Sector vs. FY2015

(Billions of yen)

	FY2015	FY2016 Forecast	Change	Reason for Change
Specialty Chemicals	142.9	114.0	-28.9	
Energy & Functional Materials	2.8	3.0	0.2	
IT-related Chemicals	19.9	6.0	-13.9	Stronger yen, lower prices
Health & Crop Sciences	77.5	57.0	-20.5	Stronger yen, lower prices, lower volumes
Pharmaceuticals	42.7	48.0	5.3	Higher volumes
Bulk Chemicals	28.8	17.0	-11.8	
Petrochemicals & Plastics	28.8	17.0	-11.8	Lower margins, lower upfront license fee revenue
Others	-7.2	-11.0	-3.8	
Total	164.4	120.0	-44.4	


(Note) After the sectors have been revised

Business Performance



Dividend Policy

We consider shareholder return as one of our priority management issues and have made it a policy to maintain stable dividend payment, giving due consideration to our business performance and a dividend payout ratio for each fiscal period, the level of retained earnings necessary for future growth, and other relevant factors.



Corporate Business Plan

Corporate Business Plan: Basic Policy

Last 10 Years

Where We Are

Where We Are Going

Pave the way for future growth (Tackle three priority management issues)

Implemented Rabigh Project

Launched DSP and acquired Sepracor/BBI

Established and expanded IT-related Chemicals Sector

Enhance financial strength

Improve profitability

Rigorously select investments

Improve asset efficiency

Restructure businesses

Exit underperforming businesses

Improve business portfolio

Further improve business portfolio

Identify areas of strength

Allocate resources to prioritized areas

Generate more cash flow

Increase profit above cost of capital

Make active and disciplined investments

Streamline balance sheet

Accelerate the launch of next-generation businesses

Environment and Energy

Life Sciences

ICT

Crossover areas

Globalization

Promote globally integrated management

Ensure full and strict compliance, establish and maintain safe and stable operations

Corporate Business Plan: Further Improve Business Portfolio

Identify areas where we have distinct strength and competitive advantage

Areas for aggressive investment and expansion

- Where we have technological advantages
- Where we have market access advantages
- Focus resources on these areas (including M&A)

Expand businesses that consistently yield profit above the cost of capital

Areas for efficiency improvement

- Where it is difficult to achieve technological differentiation
- Where demand significantly fluctuates
- Enhance cost competitiveness and pursue asset efficiency

Achieve profit above the cost of capital Maximize return on investment

Further improve business portfolio

Corporate Business Plan: Generate More Cash Flow

Enhance financial strength

Improve profitability

Rigorously select investments

Improve asset efficiency

Generate more cash flow

Increase profit above the cost of capital

Make active and disciplined investments


Streamline balance sheet

- Strengthen competitiveness
- Reduce costs

- Identify areas for aggressive expansion
- Identify investment risks
- Continuously improve cash conversion cycle
- Sell non-operating, non-strategic assets

Build and maintain robust earnings power to consistently generate strong cash flow that allows us to take advantage of large-scale investment opportunities when they arise

Corporate Business Plan's Basic Policy: Accelerate The Launch of Next-Generation Businesses



^{✓:} Next-generation businesses that have been launched or are to be launched soon.

Corporate Business Plan: Performance Targets

(Billions of yen)

	FY2015	Target	Cr
Net Sales	2,101.8	2,540.0	+4
Operating Income	164.4	200.0	_
(Equity in Earnings of Affiliates)	20.2	29.0	
Ordinary Income	171.2	210.0	_
Net Income	81.5	110.0	_

Change
+438.2
+35.6
+8.8
+38.8
+28.5

Naphtha Price
Exchange Rate

¥42,800/kl ¥120.15/\$ ¥45,000/kl ¥120.0/\$

FY2018

Challenges and Strategy for Our Major Businesses (Efforts to Create New Value)

- Progress on Efforts to Create New Value
- Cash Flow Management
- Accelerating Innovation

Challenges and Strategy for Our Major Businesses (Efforts to Create New Value)

- Progress on Efforts to Create New Value
- Cash Flow Management
- Accelerating Innovation

Progress on Corporate Business Plan: Progress on Efforts to Create New Value

Business Expansion

Restructuring

M&A

- Acquired Indian agrochemicals company
- Acquired a Phase III product candidate for Parkinson's disease
- Entered cathode materials business

Organic Growth (Production capacity expansion)

- Decided to expand methionine production capacity
- Decided to expand separator production capacity
- Decided to expand polyethersulfone production capacity
- Expanded touchscreen panel production capacity
- Proceeding with the construction of Rabigh Phase II Project
- Expanded polypropylene compound production capacity

Organic Growth (Others)

- Decided to expand R&D facilities and experimental field for agrochemicals
- Agreed to enter new collaboration with Monsanto
- Applied for U.S. FDA approval of COPD drug
- Advancing development of ADHD drug
- Advancing development of components for flexible displays
- Accelerating the shift to high value-added products at TPC


☑ Already implemented

- ☐ Being addressed
- ☑ Offering early retirement program (Sumitomo Dainippon Pharma)
- S-SBR business consolidation
- □ Polarizing film
- Film business consolidation
- □ **■**Caprolactam

[Business area]

- Life Sciences (Health & Crop Sciences)
- ☐ Life Sciences (Pharmaceuticals)
- Environment and Energy
- ICT

Progress on Corporate Business Plan: Capital Expenditure and Investment Plan



Two-thirds of investment for FY2016-FY2018 will be decided in FY2016



Accelerate our efforts to create new value

Life Sciences (Health & Crop Sciences): Challenges and Business Strategy

Value we create

Offer agrochemicals, agrochemical materials and other solutions that contribute to the improvement of food productivity



Foundations for value creation

- Capability to develop new agrochemicals
- Lineup and knowledge of biorational products
- Global sales network
- Alliance with major agrochemical manufacturers

Business trends

Long-term trends

- Increasing food demand
- Tightening of regulations on agrochemicals
- Industry consolidation
- Competition with off-patent agrochemicals

Short-term trends

Decline in methionine price

Life Sciences (Health & Crop Sciences): Challenges and Business Strategy

Efforts to Create New Value



 Establish business foundation as a global solution provider in crop protection and environmental health areas



- Enhance our global footprint
- Accelerate development of new products (B2020, A2020 and in-licensing of third-party products)
- Expand biorational and rice businesses
- Expand methionine business

Recent initiatives

- Acquired Indian agrochemical company
- Decided to enhance methionine production capacity
- ☑ Entry into the rice business

- Decided to enhance R&D facilities and experimental fields
- Agreed to build a new partnership with Monsanto

Life Sciences (Health & Crop Sciences): Enhance Global Footprint

Acquisition of Excel Crop Care, Indian Agrochemicals Company

1 Excel Crop Care Limited

Business: Development, manufacture

and sale of agrochemicals

Sales: 8.8 billion rupees (about

16.3 billion yen) in FY2015

Headquarters: Mumbai, India

2 Outline of the stock acquisition


Acquired stake: 65%


Acquisition value: 9 billion rupees

(about 13.9 billion yen)

Aim of acquisition


- Expand sales channels in India
- Leverage Excel Crop Care's brand





Increase our presence in the growing Indian market and enhance our global footprint

Life Sciences (Health & Crop Sciences): Enhance Global R&D Capabilities



Enhance global R&D structure and accelerate agrochemical development

Life Sciences (Health & Crop Sciences): Increase Methionine Production Capacity

Competitive advantage in methionine business

Integrated production from raw material

Advanced production technology

Waste liquid and gas treatment capacity

Stable supply of high quality products

Production capacity expansion


Product: DL-methionine


Production capacity: 100,000 tons

Location: Ehime Works

Start of operation: Mid 2018







Reinforce our position as Asia's leading methionine player

Life Sciences (Pharmaceuticals): Challenges and Business Strategy

Value we create

Offer pharmaceuticals and diagnostic agents that contribute to the improvement of patients' quality of life



Foundations for value creation

- R&D capabilities in the areas of psychiatric and neurological disorders and cancer
- Cooperation inside and outside the Group in the areas of regenerative and cellular medicine
- New drug development capabilities and sales networks in Japan and U.S.

Business trends

Long-term trends

- Innovation in medical technology
- Increasing pharmaceutical development costs
- Accelerated implementation of policy measures to control national healthcare spending (Japan)
- Industry consolidation

Short-term trend

 Increased use of generic drugs (Japan)

Life Sciences (Pharmaceuticals): Challenges and Business Strategy

Efforts to Create New Value



- Address the patent cliff of Latuda
- Manage the effect of policy measures to promote the use of generic drugs



- Accelerate the development of products in late-stage development
- In-license and acquire third-party products under-development
- Accelerate the development of regenerative and cellular medicine
- Reform cost structure (Japan and U.S.)

Recent initiatives

- Acquisition of Parkinson's disease
 Progress in the development of drug*
- Filed for U.S. FDA approval of COPD drug
- Progress in the development of cancer stem cell inhibitor


- ADHD drug
- Launched early retirement program in Japan (Sumitomo Dainippon Pharma)

^{*} Acquired Cynapsus Therapeutics Inc. in October 2016

Life Sciences (Pharmaceuticals): Post-LATUDA Efforts

Despite an expected earnings decline in FY2019 due to the expiration of the U.S. patents for LATUDA in the second half of FY2018, we aim to achieve an early recovery and growth in FY2020 and beyond by launching new products and expanding their sales

Net sales



Main launch products (planned)

Oncology area

- Anticancer drug Napabucasin (Japan and U.S.)
- Anticancer drug Amcasertib (Japan and U.S.)
- Anticancer drug DSP-7888 (Japan and U.S.)

Other areas

- SUN-101 for chronic obstructive pulmonary disease (COPD) (U.S.)
- Dasotraline for attention deficit hyperactivity disorder (ADHD) / binge eating disorder (BED) (U.S.)
- SB623 for chronic stroke (U.S.)
- APL-130277 for Parkinson's disease (U.S.)
- Lurasidone atypical antipsychotic (Japan)
- DSP-1747 for non-alcoholic steatohepatitis (Japan)

(Assumption) NHI prices to be revised in FY2018 and FY2020

Life Sciences (Pharmaceuticals): Post-LATUDA Efforts — Product Development

Application for approval of drug for chronic obstructive pulmonary disease (COPD)

Efficacy

Chronic obstructive pulmonary disease (COPD)

Feature


- 1. Administered by nebulizer*
- 2. Short administration time (2 to 3 minutes)

Development plan

At present:

Applied for approval (U.S.)





* Nebulizer: a device used for inhaling a medicinal drug

eFlow®, nebulizer for SUN-101

Anticipating peak sales of 50 billion yen

Acquisition of Parkinson's disease drug*

Efficacy

"Off" episodes of Parkinson's disease

Feature

Sublingual thin film

Development plan



Administration of APL-130277

At present: In phase III clinical trials

(North America)

FY2017: Submit new drug application

In 2018: Possible approval

* Acquired in the transaction of acquiring Cynapsus Therapeutics Inc. in October 2016 for 635 million dollars

Anticipating peak sales of 50 billion yen

Making progress in new product development and in-licensing for post-LATUDA period

Environment and Energy: Challenges and Business Strategy

Value we create

Offer highly functional materials and solutions for environmentally friendly products, such as eco-cars



Foundations for value creation

- Capability to develop and offer highly functional products
- Manufacturing technology for highly functional products

Business trends

Long-term trends

- Demands for sustainable society
 - Measures for addressing climate change issues
 - Measures for addressing energy and resource issues
- Tightening of various regulations
- Global competition

Short-term trend

 Intensifying competition in some businesses

Environment and Energy: Challenges and Business Strategy

Efforts to Create New Value



- Grow the battery component business into a core business
- Nurture eco-car component business




- Enhance the lineup of battery components and their production capacity
- Expand the use of existing materials in eco-car parts
- Restructure underperforming businesses


Recent initiatives and issues being addressed


- Entered cathode materials business
- Expansion of separator production capacity
- Issues being addressed

- Decided to increase
 PES production capacity
- Began the study of S-SBR business integration

Environment and Energy: Decided to Increase Lithium-Ion Secondary Battery Separator Production Capacity







Separator production capacity expansion plan

Production capacity: South Korea production capacity to be

quadrupled

Start of operation: In stages from August 2017

Separator production capacity



	Future
Japan	Approx. 100 million m ²
South Korea	Approx. 300 million m ²
Total	Approx. 400 million m ²

Expand market share of lithium-ion secondary battery separator for automotive use

Environment and Energy: Entry into Cathode Materials Business

Profile of Tanaka Chemical Corporation

Business: Manufacture and sale of cathode materials and catalyst raw materials

Net sales: Approx. ¥15.3 billion in FY2015

Became Sumitomo Chemical's subsidiary through private share placement

Shares acquired:


10.5 million (subscription value: Approx. ¥6.6 billion)

Shares owned:

12.7 million (investment ratio of 50.1%)

Aim of acquisition

Accelerate development and launch of highly functional cathode materials for automotive batteries by leveraging the two companies' strengths.



Entry into the cathode materials business, aiming to have our products adopted for automotive batteries as soon as possible

ICT: Challenges and Business Strategy

Value we create

Offer highly functional components that contribute to the improvement of display performance



Foundations for value creation

- Close relationships with excellent customers (customer-oriented supply chain)
- Material development capability as an diversified chemicals manufacturer

Business trends

Long-term trends

- Maturing LCD markets (Growing production in China)
- Widening use of OLED displays (Growing production in Korea, China, etc.)
- Flexible displays beginning to be adopted

Short-term trends

 Rebounding demand for LCD materials

іст: Challenges and Business Strategy

Efforts to Create New Value



 Address the generational shift in display technology and growing LCD production in China




- Establish cost advantage in the LCD component business
- Develop new products in the OLED component business and make investment in a timely manner

Recent initiatives and issues being addressed


- ✓ Completed the expansion of touch screen panel production capacity
- ✓ Accelerate the development of flexible display components
- □ Reform cost structure of the polarizing film business
 (including a restructuring of the supply capabilities)

іст: Business Life Cycle Management in ICT Area



Develop the next-generation business pipeline in anticipation of generational shift in display technology

іст: Sales Outlook of Display Material Business



Recent initiatives

LCD components

- ☑ Increased use of materials made in-house
- Restructured production capabilities to enhance competitiveness

OLED display components

- Expanded touchscreen panel production capacity
- Decided to mass-produce and launch coated retardation film
- Making progress in the development of PLED light-emitting materials

Shift the pivot of the business from LCD components to OLED components

Bulk Chemicals: Challenges and Business Strategy

Value we create

Offer petrochemical products sought by customers



Foundations for value creation

- Access to cost-competitive ethane
- Brand power in the Asian market
- Capability to develop high value-added products
- Close relationships with prominent customers

Business trends

Long-term trends

- Stable growth in demand
- Increase in supply from new plants using costcompetitive gases as feedstock

Short-term trend

 Solid demand and supply balance in the Asian market

Bulk Chemicals: Challenges and Business Strategy

Efforts to Create New Value



 Further improve production operations on a region-by-region basis



- Enhance high value-added products business (Singapore and Japan)
- Achieve stable operation (Rabigh Phase I project)
- Achieve early start-up (Rabigh Phase II project)


Recent initiatives and issues being addressed


- Making progress in construction of Rabigh phase II project
- Accelerating the shift to high value-added products at TPC
- Expanding polypropylene compound production capacity

- ✓ Integration of film business
- □ Restructuring of the caprolactam business
 - Implemented
 - ☐ Issues being addressed

Bulk Chemicals: Rabigh Project

Petro Rabigh's Net Income





Progress on Corporate Business Plan: Progress on Efforts to Create New Value

Business Expansion

Restructuring

M&A

- Acquired Indian agrochemicals company
- Acquired a Phase III product candidate for Parkinson's disease
- Entered cathode materials business

Organic Growth (Production capacity expansion)

- Decided to expand methionine production capacity
- Decided to expand separator production capacity
- Decided to expand polyethersulfone production capacity
- Expanded touchscreen panel production capacity
- Proceeding with the construction of Rabigh Phase II Project
- Expanded polypropylene compound production capacity

Organic Growth (Others)

- Decided to expand R&D facilities and experimental field for agrochemicals
- Agreed to enter new collaboration with Monsanto
- Applied for U.S. FDA approval of COPD drug
- Advancing development of ADHD drug
- Advancing development of components for flexible displays
- Accelerating the shift to high value-added products at TPC

☑ Already implemented

- ☐ Being addressed
- ☑ Offering early retirement program (Sumitomo Dainippon Pharma)
- ☐ S-SBR business consolidation
- □ Polarizing film
- Film business consolidation
- □ Caprolactam

[Business area]

- Life Sciences (Health & Crop Sciences)
- ☐ Life Sciences (Pharmaceuticals)
- Environment and Energy
- ICT

Challenges and Strategy for Our Major Businesses (Efforts to Create New Value)

- Progress on Efforts to Create New Value
- Cash Flow Management
- Accelerating Innovation

Cash Flow Management: Cash Flow Target

(Rillians of van)

				(Billions of yen)
			2016-2018 (Target)	
	2010-2012	2013-2015	After investments in strategic M&A	(Reference) Before investments in strategic M&A
Cash flows from operating activities	472.3	716.4	680.0	680.0
Cash flows from investing activities	-445.7	-245.5	-800.0	-540.0
Free cash flows	26.6	470.9	-120.0	140.0
(Billions of year				
			End of FY2018 (Target)	
	End of FY2012	End of FY2015	After investments in strategic M&A	(Reference) Before investments in strategic M&A
Interest-bearing liabilities	1,060.6	831.5	1,000.0	850.0

liabilities

Cash Flow Management: Measures to Improve Cash Flows

Operating cash flows

 Stronger yen than planned (Weaker business environment in some businesses)

Investment cash flows

- Strategic M&A investments implemented
- Increase in capital investment projects

Lower free cash flows and increased interest-bearing liabilities



Measures

Selective investment

- ✓ More selective investment
- ✓ Quickly decide whether to continue underperforming businesses

Asset sales


✓ Accelerate asset sales

Others

- ✓ Redouble rationalization efforts
- Use cash reserves effectively

Rigorously select and implement investments necessary for sustainable growth, while maintaining sound financial condition

Cash Flow Management: Interest-Bearing Liabilities and Debt to Equity Ratio



Challenges and Strategy for Our Major Businesses (Efforts to Create New Value)

- Progress on Efforts to Create New Value
- Cash Flow Management
- Accelerating Innovation

Progress in Corporate Business Plan: Accelerating Innovation (IoT Project)

Digital Global SCM

Global integration and upgrading of the core business IT system

- Enhancement of external collaborations
- Real time
- Strengthening of data analysis functions
- Enhancement of simulation functions
- Improvement of user interface

Visualize global supply chain information on a real time basis

loT Project

Digital R&D

Sophistication

e.g., Development of new materials from a new perspective

Efficiency

e.g., Use of AI to improve speed and quality of search and research for patents and papers

Key technologies and know-how

Sharing know-how for Al utilization

Development of the environment for machine translation

Digital Back Office

Paperless <

Groupware utilization

Work style innovation and improvement of operational efficiency Greater flexibility of system Reduction of IT system expenses

Digital workspace

Cloud

Digital Plant

Digital Worker

 Improvement of safety and efficiency of work process

Digital Asset

Maximization of facility capacity

Digital Operation

 Optimization of operation and improvement of operational efficiency

Digital Infrastructure

 Modernization of digital infrastructure of plants

Utilizing latest information technologies, including big data and AI in R&D and intellectual property-related activities


1 Utilization of information collection and analysis tools

Concept search tool

Text mining tool

Visualization tool

Improve speed and accuracy of information collection



Introduction of electronic lab notebook



- Improve efficiency of lab notebook preparation
- Introduce a format to be followed in lab notebook entry, promoting information sharing




Improve R&D productivity

- Utilization to support decision-making (under consideration)
 - Utilization of big data inside and outside the company




Improve productivity of R&D activities and accelerate the launch of next-generation businesses

Progress in Corporate Business Plan: Accelerating Innovation (Technology Development by Open Innovation)



Accelerate the development of next-generation businesses by leveraging both internal and external expertise

Progress in Corporate Business Plan: Accelerating Innovation (Business Development by Open Innovation)



Accelerate the development of next-generation businesses by leveraging both internal and external expertise

Sumitomo Chemical's Value Creation

What Sumitomo Chemical Strives To Be

Business Philosophy

- ◆ Commit ourselves to creating new value by building on innovation
- ♦ Work to contribute to society through our business activities
- Develop a vibrant corporate culture and continue to be a company that society can trust

Core Competence Capabilities to develop innovative solutions by leveraging its technological expertise in diverse areas

Capabilities to reach global markets

Loyal employees



Challenges & Business Opportunities

Solve issues facing society

Environment

Food

Resources and energy

Improve quality of life and build an affluent and comfortable society

Health promotion


Comfortable life






Achieve sustained growth by creating new value through innovative technologies

Achieve Sustained Growth



Become a more resilient Sumitomo Chemical that achieves sustained growth


Initiatives For Enhancing Enterprise Value



Promote initiatives for enhancing enterprise value (ROI)

ESG Initiatives: Corporate Governance

Change in the Functions of Board of Directors



ESG Initiatives: SDGs

SDGs (Sustainable Development Goals)

The Sustainable Development Goals, adopted by the United Nations in 2015, consist of 17 goals and 169 targets, and represent a historical agreement involving all 193 UN member nations

Sumitomo Chemical's initiatives towards achievement of SDGs

Time	Initiatives
Sep. 2015	SDGs adopted at United Nations Sustainable Development Summit
Feb. 2016	SDGs discussed at SCC's CSR Promotion Committee
May 2016	SDGs webpage opened on SCC's website
June 2016	Launched Sustainable Tree program Workshop held at the Officers Liaison Meeting (4 times)
July 2016	Internal seminars (twice with 400 participants in total)
Aug 2016	Presented SCC's policy on SDGs in its CSR report
	Reported its SDGs initiatives at the Board of Directors Meeting

Reference: 17 Sustainable Development Goals









































An initiative for officers and employees to post on a dedicated website their ideas as to what they can do at work and in their private life to bring about a society with hope for future.

Period: 100 days from June to October 2016

Target: Officers and employees of all group companies

Number of posts: 6,005 in total


プライパシー保護のため、この画像の自動ダウンロードをブロックしました

ESG Initiatives: Sumika Sustainable Solutions

What are Sumika Sustainable Solutions?

We certify as "Sumika Sustainable solution" our products and technologies that contribute to mitigating global warming and reducing environmental burden. We promote the development and the use of these products and Technologies while also enhancing information disclosure to support the efforts to achieve the SDGs and build a sustainable society.

Certified products and technologies: 21 products (Nov.2016)




Certified products and technologies

- Contribution to promoting the use of EVs
 - Lithium-ion secondary battery separator Pervio®

reducing the weight of aircraft

- Contribution to fuel efficiency improvement by
 - Polyethersulfone Sumikaexcel®
- Significant energy saving in CO₂ separation in hydrogen production
 - CO₂ separation membrane
- Reduced GHG emissions by reducing the nitrogen content in livestock waste
 - Feed additive methionine **Sumimet®**





Offer solutions to build a sustainable society -> Contribute to measures for mitigating global warming

Sumitomo Chemical's Value Creation

Improve ROI

Improve profit margin

Improve asset turnover rate

Improve Growth Rate

Concentrate management resources on the three growth areas and cross-over areas

Environment and Energy

Life Sciences

ICT

Continuation of the ESG initiatives

Environment

Contribute to sustainable development of society through business

Society

Build good relationships with stakeholders

Governance

Improve the effectiveness of governance



Towards achieving continuous value creation

Creative Hybrid Chemistry



Cautionary Statement

Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.